Mechanisms of Action

The unique combination of properties based on secretion of diverse biomolecules underscores the importance of mesenchymal adult lineage stem cells (MLCs) as a platform for the development of cell-based regenerative medicine therapies. Our lead MLC products have been developed through proprietary processes optimized to express certain biomolecules implicated in the mechanisms of action by which the MLC product is thought to modify outcomes for the specific target condition.

Examples of our products and the biomolecules involved in their characterization are:

    • MPC-150-IM is designed for local delivery to damaged heart muscle and to allow the MLCs to secrete biomolecules involved in myocardial neovascularization, cardiomyocyte survival, cardiomyocyte precursor migration and proliferation, and reduction in fibrosis and myocardial scarring. Biomolecules include stromal cell-derived factor 1, Angiopoietin-1, vascular endothelial growth factor (VEGF), hepatocyte growth factor, and matrix metalloproteinases.
    • MPC-06-ID is administered by local delivery to degenerating intervertebral discs to allow our MLCs to secrete biomolecules involved in enhanced migration and proliferation of intervertebral disc progenitor cells, and in enhanced proteoglycan and collagen synthesis in the disc nucleus and annulus. These biomolecules include Angiopoietin-1 and transforming growth factor beta.
    • MPC-300-IV, TEMCELL® HS. Inj. and MSC-100-IV are product candidates that are designed to be intravenously delivered in systemic conditions of excessive inflammation and to allow the MLCs to secrete biomolecules involved in immunomodulation, particularly prostaglandin E2, and indoleamine 2, 3-dioxygenase, in response to activation by pro-inflammatory cytokines such as tumor necrosis factor-alpha, and interleukin-1. Release of immunomodulatory biomolecules by these MLC products acts to polarize pro-inflammatory M1 monocytes to anti-inflammatory M2 monocytes, and to switch activated T helper cells 1 and 17 (Th1 and Th17), respectively, to Th2 cells and FOXP3 T regulatory cells.
    • MPC-25-OSTEO is designed to allow our MLCs to secrete biomolecules involved in osteoblast migration and bone vasculature, both features of new bone formation. These biomolecules include various bone morphogenic proteins and VEGF.